RXi Pharmaceuticals (RXII) Getting Somewhat Positive Media Coverage, Analysis Finds

Headlines about RXi Pharmaceuticals (NASDAQ:RXII) have been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. RXi Pharmaceuticals earned a daily sentiment score of 0.06 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 44.1419378961307 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the news stories that may have impacted Accern’s analysis:

Shares of RXi Pharmaceuticals (RXII) traded down $0.11 during mid-day trading on Friday, reaching $4.42. 17,265 shares of the company traded hands, compared to its average volume of 62,428. RXi Pharmaceuticals has a 52 week low of $3.20 and a 52 week high of $11.20. The stock has a market capitalization of $10.73, a PE ratio of -0.41 and a beta of 1.38.

RXi Pharmaceuticals (NASDAQ:RXII) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($1.10) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($1.10). During the same quarter in the previous year, the firm posted ($3.40) earnings per share.

ILLEGAL ACTIVITY WARNING: This article was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3147772/rxi-pharmaceuticals-rxii-getting-somewhat-positive-media-coverage-analysis-finds.html.

RXi Pharmaceuticals Company Profile

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

Insider Buying and Selling by Quarter for RXi Pharmaceuticals (NASDAQ:RXII)

Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.